DAXOR (DXR) Company Report

Daxor Corporation entered into a definitive securities purchase agreement on January 23, 2026, for a registered direct offering.
The company issued and sold an aggregate of 765,958 registered shares of common stock at $11.75 per share.
The offering resulted in net proceeds of approximately $8,142,006, after placement agent fees and expenses.
The closing of the offering took place on January 26, 2026.
The net proceeds from the sale of shares will be used for general corporate purposes, including working capital.

Jan 26, 2026, 9:58 PM

Daxor Corporation Announces Registered Direct Offering

DXR

Daxor Corporation (DXR) has entered into a definitive agreement for a registered direct offering of 765,958 shares of its common stock at a purchase price of $11.75 per share.
The offering is expected to generate approximately $9 million in gross proceeds and is anticipated to close on or about January 26, 2026.
The net proceeds from the offering will be used for general corporate purposes, including working capital.

Jan 23, 2026, 1:00 PM

Daxor Announces FDA Clearance of Next-Generation BVA Analyzer and Clinical Validation

DXR

Product Launch

New Projects/Investments

Daxor Corporation (DXR) has debuted its newly FDA-cleared, next-generation BVA analyzer, which offers enhanced ease of use, speed, and over 95% accuracy for data-driven fluid management.
This new analyzer targets a multi-billion-dollar market and positions Daxor to capture significant commercial share.
New clinical data presented at the HFSA meeting validated Daxor's BVA technology, demonstrating zero unplanned hospital admissions for optimally managed heart failure patients and improved survival and reduced readmissions for LVAD patients.

Sep 30, 2025, 12:00 PM

Daxor Corporation Provides Mid-Year Corporate and Financial Update

DXR

Revenue Acceleration/Inflection

Product Launch

New Projects/Investments

Daxor Corporation received FDA Clearance for its new rapid, lightweight Blood Volume Analysis System in August 2025, which is three times faster, portable, and a fraction of the size of the existing BVA-100.
The operating division experienced a 73 percent increase in unaudited revenues for the six-month period ended June 30, 2025, compared to the six-month period ended June 30, 2024.
Net Asset Value (NAV) increased to $7.15 per share as of June 30, 2025, up $0.40 per share from $6.75 per share at June 30, 2024.
Market penetration accelerated with three new facility adoptions in July 2025 and the BVA diagnostic reaching two new U.S. Healthcare Systems in May 2025.